Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EBIT (2020 - 2024)

Immuneering has reported EBIT over the past 5 years, most recently at -$18.6 million for Q4 2024.

  • Quarterly results put EBIT at -$18.6 million for Q4 2024, down 13.84% from a year ago — trailing twelve months through Dec 2024 was -$64.1 million (down 9.69% YoY), and the annual figure for FY2025 was -$59.4 million, up 7.33%.
  • EBIT for Q4 2024 was -$18.6 million at Immuneering, down from -$15.3 million in the prior quarter.
  • Over the last five years, EBIT for IMRX hit a ceiling of -$3.6 million in Q2 2020 and a floor of -$18.6 million in Q4 2024.
  • Median EBIT over the past 5 years was -$13.2 million (2022), compared with a mean of -$11.7 million.
  • Biggest five-year swings in EBIT: plummeted 121.56% in 2021 and later decreased 4.4% in 2024.
  • Immuneering's EBIT stood at -$5.8 million in 2020, then tumbled by 90.45% to -$11.1 million in 2021, then fell by 25.81% to -$14.0 million in 2022, then fell by 16.57% to -$16.3 million in 2023, then fell by 13.84% to -$18.6 million in 2024.
  • The last three reported values for EBIT were -$18.6 million (Q4 2024), -$15.3 million (Q3 2024), and -$14.9 million (Q2 2024) per Business Quant data.